Eurofins Viracor and Cornell University have signed an exclusive licensing agreement to commercialise various new assays for transforming the clinical management of transplant and Covid-19 patients impacted by infections and tissue damage.
The Cornell University team has developed a new non-invasive blood test that can be used as an alternative to biopsy for measuring organ injury from Covid-19.
Using circulating cell-free DNA (cfDNA), the test measures the damage that Covid-19 inflicts on organs, cells and tissues.
The cfDNA is an analyte used to monitor critical complications of hematopoietic cell transplantation (HCT) for many cancers and blood disorders, including infection, graft-versus-host disease, graft failure and disease relapse.
In a statement, Eurofins Viracor said that the collaboration will expand access to a new blood-based cfDNA methylation sequencing assay to detect or predict major complications related to allogeneic HCT at an early stage.
This will help to improve the care of stem cell transplant patients.
Furthermore, the company intends to commercialise the new cfDNA test in another application, as it can also be used to identify the presence of urinary tract infections in kidney transplant patients as well as assess damage to the kidney and bladder.
Eurofins Viracor said in a statement: “With the combined strength of Eurofins Viracor and its affiliated companies Transplant Genomics and Eurofins Donor & Product Testing and their innovative transplant testing portfolios, the strategic collaboration with Cornell University marks another critical step in the mission of the Eurofins US Transplant Diagnostics companies to address unmet needs across the continuum of transplant patient care.”
Last April, the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) approved the Viracor TRAC donor-derived cell-free DNA test and TruGraf blood gene expression test from Eurofins Viracor and Transplant Genomics.